Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd.

Transcription

1 Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd.

2 Roche recognizes changes in China Strong economic development over the last 20 years Reorganization of Healthcare System (e.g. implementation of GCP and GLP in Hospitals, re-organization of Chinese Pharmaceutical industry) Implementation of new laws (e.g. intellectual property law and regulations) Re-organization of Academic institutions towards Centers of excellence Promotion of Hi-Technology (e.g. Bio-Technology) Shanghai: the Biotechnology hub of China Central and local government support innovation based industries Increasing number of highly educated Chinese (and returnees) in drug discovery research

3 Shanghai and Pudong

4 The ZJ Pharma Valley r

5 Contribute to ZJ - HiTech Park growth ZhangJiang Pharma Valley Shanghai Roche Pharmaceutical Ltd Southern Genomics Center Shiguang Hospital Shanghai Institute of Materia Medica Shanghai TCM University Roche R&D Center (China) Ltd Source: ZJ HiTech Park

6 China IPR Patent law established in st Revision in 1992 Expanded patent coverage to substance, formulation etc. Extended coverage time to 20 years Enforce the execution 2 nd Revision in 2000 Prepare for WTO Improved patent application, evaluation and approval process Strengthen patent enforcement China patent applications 85-04: Mio, annual growth rate 18.9% 2004: 353 K

7 Roche R&D Center (China) Co. Ltd Owned by Roche Is a part of the Roche Global Research Located at Shanghai ZJHT Park Initially will be staffed with 40 scientists Conduct medicinal chemistry in lead generation and optimization as a part of Roche Global Research Collaborate and create partnership in drug discovery Create and protect IP in China Strong co-operation with SRPL

8 Establishment of RRDCC Building infrastructure Research infrastructure Recruitment Feb 04 Site Selected Oct 04 Site Opened Nov 04 Site Setup Advertising Hiring Training Jan 04 Site Announcement July 04 Site Construction Dec 04 Site Operation

9 Roche R&D Collaboration Projects in China Project Description Collaboration Partner Schizophrenia related genes Diabetes II/ Obesity related genes Alzheimer s disease related genes Diabetes II/ Obesity (Hypertension) Obesity / Hypertension China Human Genome Center, Shanghai China Human Genome Center, Shanghai China Human Genome Center, Beijing China Human Genome Center, Beijing Sino-German Genome Center, Beijing Chronic Obstructive Pulmonary Disease Shanghai Chemistry Outsourcing (Intermediates)Shanghai Institute of Organic Chemistry Total Investment >4.5 million USD in the past few years

10 Outlook: RRDCC as Platform organization Co-operation support functions (SRPL) Outsourcing & Project management RRDCC In-house research & Joint projects In-licensing support (IPR) Communication with Authorities and KOL Training & Technology transfer Roche is sending a very strong message to both the Chinese authorities and the scientific community throughout the country that we share their vision of the future in which China will play an increasingly important role in healthcare R&D

11 Potential new Biotechnology valleys in China Major Pharmaceutical companies Hospitals Academic Competence Centers & Investors (VC, Banks et al.) Biotech Startups Ref.: Boston, San Diego

12 Summary As a pioneer in Drug discovery among MNCs in China, Roche understands itself as a reliable partner to Government, Academia and Biotech industry. The creation of RRDCC represents a major long-term commitment to China and reinforces the importance of China as a global player in the field of biomedical science as and a growing market for our healthcare products. Roche s commitment is also based on confidence in China s embrace of WTO principles and responsible approach to intellectual property protection.